Demo

AI for Diabetic Retinopathy

Book free trial to see how AI can detect DR and 70+ other pathologies/biomarkers

Book Intro

Altris AI is an FDA-cleared and CE-marked platform for OCT scan analysis that uses AI to detect the earliest signs of Diabetic Retinopathy before they become clinically visible. It provides:

Quantitative analysis of DR biomarkers’ area and volume.

Swift detection and localization of pathological changes.

Tracking changes of DR over time acrosss multiple examinations.

By combining OCT imaging with Altris AI, eye care specialists enhance diagnostic precision, ensure earlier intervention, and optimize long-term visual outcomes for their patients.

Platform overview

Only practical features for eye care specialists and clinical research

GDPR compliant (all data is encrypted), CE-certified, and FDA- cleared (510k).

William C. Fruchtman, Optometry Owner

I was really excited to find Altris AI to bolster my skills identifying certain macular diseases. It's a great program and has guided me in the diagnosis of complex cases.

3 Oct, 2024
Scott Sedlacek Optometry Owner

Altris AI identified and described pathology that I could not. Early detection changes the treatment from doing nothing to something. Also, Altris AI described something that I thought was worse than it was. Saved me from over-referring. Patients love to see the color-coded images which help as an educational tool and get buy-in on the treatment plan which helps compliance.

1 Feb, 2024
Richard Clare Optometry Owner

We are adding a new OCT to one of our practices and may benefit from some extra support with AI to speed up the interpretation of results and assist the busy Optometry team.

Dec 7, 2023
/

Make informed decisions based on objective insights.
Leverage the power of longitudinal data analysis for AI DR screening.

Altris AI offers standardized and reproducible examination with accurate volumetric and area measurements down to micrometers.

Add OCT examinations from different visits

Detect all the biomarkers of DR with color-coding

Explore DR biomarkers in terms of area, volume

Track changes in DR biomarkers over time

How Altris AI works?

And what's the value of using Artificial intelligence for Diabetic Retinopathy

  • img
  • img
  • img
  • img
  • img
  • img
  • img
  • img

Altris AI is a web platform created by retina experts for all eye care specialists and clinicians.

We’ve collected millions of OCT scans, and our team graphically labeled thousands of them to create the Altris AI system that can:

Detect over 70 pathologies and biomarkers, including early DR indicators.
Measure and track pathological changes across multiple examinations.

 

Formats

DICOM format will help you to extract maximum information. However, the system works with all
data formats, such as jpg, and png

 

OCT equipment

Altris AI is vendor-neutral. We work with all the OCT equipment producers

 

OCT reports

We create comprehensible OCT reports for patients and doctors

For Clinical Research

What you get with Altris AI:

Contact us:

  • Accelerate ophthalmic drug trial with AI
  • Detect DR and its biomarkers ( +70 retinal pathologies and biomarkers) with AI
  • Track the progression of biomarkers to assess drug efficiency
  • Enroll the right patients based on fast biomarkers detection
  • Reduce costs associated with manual scan review with automated analysis
  • Reduce human made errors to the minimum

For Eye Care

We support you through the whole way

Contact us:

  • 14 Days of Free Trial to see the value
  • Support during the whole trial period
  • Early glaucoma assessment module access
  • CE-certified, GDPR, HIPAA compliant, FDA clearance
  • Integration support with any EHR, EMR system.
  • Cloud data storage/on premises possible
  • Access to the whole functional during trial